The quality control microbiology lab serves a valuable function in the pharmaceutical manufacturing environment in terms of providing information on the biological quality of the products being produced. The major tests are familiar to us all – Microbial Limits, Sterility Tests, and Antimicrobial Effectiveness Tests. All of these tests require strict attention to detail for reproducible results, and the compendium also provides guidance on the quality control aspects of laboratory operations. In the first half of this presentation, Dr. Sutton will provide a brief overview of both of these aspects of microbiological quality control with guidance for the listener on how to further research best practice as described in the compendium. In the second half, Mrs. Kerrigan will describe how ATCC is striving to meet the current needs of the quality control microbiology lab.

Vector-borne diseases are a major public health concern, affecting billions of people worldwide. Due to the complexity of vector-borne pathogen transmission, these illnesses are among the most difficult infectious diseases to predict, prevent, and control. Moreover, many vector-borne pathogens can be challenging to culture, require high-containment facilities, or are on the commerce control list, making them difficult to study. To support the development of rapid diagnostic tools and innovative therapeutics, ATCC has synthetically derived nucleic acids that represent key target regions from a number of infectious microorganisms, including dengue virus, West Nile virus, and Eastern equine encephalitis virus, among others. These standards are quantitated, stable, can be handled in BSL-1 conditions, and don’t require permits for international shipping. In this webinar, we will discuss emerging vector-borne microbial pathogens, molecular and biological products from ATCC that support vector-borne research, and will demonstrate the use of ATCC synthetic molecular standards microbial detection and quantification.

Discovering ATCC Hematopoietic Progenitor Cells

Model Systems to Study the Immune and Cardiovascular Systems


The cellular components of blood originate in bone medullary cavities. In the process of becoming fully functional, hematopoietic cells undergo a program of differentiation which begins in the marrow and may be completed in the peripheral tissues and organs such as blood, lymph, thymus, and spleen. The result is a diversity of cell types, each of which displays specific transport, hemostatic, and immune functions. Hematopoietic research tools have high value for investigating the pathogenesis of anemia and autoimmune diseases, and are useful controls in liquid tumor studies. In this webinar, ATCC scientists will discuss recent developments in developing models of hematopoiesis using immunological cells such as CD34+ bone marrow cells, CD14+ peripheral blood monocytes, and primary peripheral blood mononuclear cells.

Accuracy Matters

Proficiency Testing Programs Offer Dependable Materials for Assessments with Trackable Online Results


LGC is a leading life sciences measurement and testing business that offers a comprehensive range of products and services, including proficiency testing programs from LGC’s custom-built facility in the north of England. This presentation will discuss the general requirements and purpose of proficiency testing with reference to ISO/IEC 17043:2010. There will also be a brief overview of the different programs and samples offered by LGC, and available from ATCC in the U.S., including program logistics, sample preparation and quality control, and the statistical assessment and reporting of results.


The emergence of 3D tissue modeling raises new possibilities for the study of complex physiological processes in vitro. Advances in cell isolation, media development, substrates, and growth surfaces are leading to protocols that provide more functionality than traditional 2D cell culture. These models may provide a more predictive analysis and result in a more streamlined process of drug discovery and development. In this webinar, we will discuss recent developments in 3D modeling using ATCC primary and hTERT immortalized cells in areas such as angiogenesis, wound healing, and respiratory studies.

Droplet Digital PCR (ddPCR) is an elegant technology that permits accurate and absolute quantification of target nucleic acid molecules. By subpartitioning a PCR reaction into thousands of nanoliter sized droplets, amplifying, and subsequently individually interrogating them, ddPCR allows for increased quantitative resolution, enhanced detection of difficult to amplify targets, better reproducibility, and simplified data analysis. This webinar will provide a technical overview of ddPCR from technical and workflow related perspectives as well as review key applications such as copy number variation (CNV) analysis, rare mutation detection (RMD) analysis, and standard free (stand-alone) absolute quantification of nucleic acids.

Dopaminergic neurons play significant roles in motor, reward, and motivational behavior related circuits throughout the brain. To date, there are few continuous in vitro models available to laboratories in research, industry, and academia for studies related to basic dopaminergic cell biology or high throughput screening. Here, we propose the use of a human model system, LUHMES cells, to study dopaminergic neuron cell biology. During this webinar, we will highlight some of the advantages of using LUHMES cells, as well as examples of how they have been used in drug screening and to study the molecular mechanisms related to Parkinson’s Disease.

ATCC® Genetic Alteration Cell Panels

Effective Tools for High Throughput Screening Using Corning® Epic® Technology


Extensive genomic™ sequencing efforts in recent years have provided detailed profiles of the somatic gene mutations that occur in a wide range of human cancers. In order to facilitate basic and translational cancer research, ATCC has designed and validated a number of Genetic Alteration Cell Panels targeting the key molecular pathways identified in these studies. To demonstrate suitability of the panels for high throughput screening, the EGFR panel was selected for evaluation using Corning Epic Technology, a label-free platform that uses optical biosensors for high sensitivity biochemical and cell-based assays. In this webinar, we will discuss how the combination of Epic Technology and the EGFR Genetic Alteration Panel offers convenient tools to screen for ligands or biologics that directly target or affect EGFR receptor biology.

Influenza remains one of the most significant infectious diseases worldwide, causing acute respiratory tract illnesses and accounting for 25% of infections that exacerbate chronic lung infections. To date, several epidemics and four major influenza pandemics have been recorded. Influenza viruses have caused an estimated 3 million cases of serious illness and around 500,000 deaths annually worldwide. Influenza infections are primarily and effectively controlled by vaccines that elicit protective immunity. Influenza viruses undergo rapid antigenic shift and drift that results in the emergence of new strains each year. Therefore, influenza vaccines need to be reformulated every year to match the circulating strains. In this webinar, we will provide an overview of the influenza virus and will explore the current treatment strategies for influenza infections. We will also highlight viral strains and associated materials offered by ATCC that can be used in influenza research or in the development and validation of novel preventative and therapeutic techniques.

ATCC® Human Pluripotent Stem Cells

Enabling Research through Standards


Induced pluripotent stem cells (iPSCs) provide a powerful tool to model human disease in relevant cell types. iPSCs may be generated from patients of any genetic background, and possess the capacity to differentiate into almost any desired terminal cell type. In this webinar, we will focus on ATCC's approach in generating and providing standardized, quality controlled, and highly characterized human iPSCs lines with its complete culture systems. We will also highlight the characterization of LRRK2 Parkinson’s patient-derived iPSC lines by whole-exome sequencing.